Med BioGene, Inc. operates as a life science company, which engages in the development and commercialization of genomic-based clinical laboratory diagnostic tests. It focuses on managing the license and rights for GeneFx Lung, prognostic genomic-based test for non-small-cell lung cancer. The company was founded on April 28, 2006 and is headquartered in Vancouver, Canada.
Company profile
Ticker
MBI.H
Exchange
Website
CEO
Iain Weir-Jones
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
RW
Registration withdrawal request
2 Feb 12
8-A12B/A
Registration of securities on exchange (amended)
22 Jun 10
F-1/A
Registration statement (foreign) (amended)
22 Jun 10
8-A12B
Registration of securities on exchange
18 Jun 10
F-1/A
Registration statement (foreign) (amended)
9 Jun 10
F-1/A
Registration statement (foreign) (amended)
27 May 10
F-1/A
Registration statement (foreign) (amended)
7 May 10
F-1/A
Registration statement (foreign) (amended)
23 Apr 10
F-1/A
Registration statement (foreign) (amended)
13 Apr 10
F-1/A
Registration statement (foreign) (amended)
19 Mar 10
Latest ownership filings
No filings